Merck presents first Phase 3 INTerpath — 001 data on intismeran plus Keytruda in resected melanoma at ESMO 2026
Merck flagged first-time pivotal Phase 3 data from its oncology pipeline for presentation at ESMO 2026 in Madrid. Results have not been presented yet; three late-breaking Presidential Symposia will feature melanoma and endometrial cancer studies. Key readouts cover intismeran autogene with Keytruda in resected melanoma